Differential striatal levels of TNF-α, NFκB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: Role in orofacial dyskinesia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 6, 2008, Pages 1473-1478

  Bishnoi, Mahendra ^a   Chopra, Kanwaljit ^b   Kulkarni, Shrinivas K ^a,b  

^a PANJAB UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Atypical neuroleptics; NF B; Orofacial dyskinesia; Tardive dyskinesia; TNF ; Typical neuroleptics

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN PROTEIN; CLOZAPINE; DOPAMINE; HALOPERIDOL; RISPERIDONE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FACE; HUMAN; INVOLUNTARY MOVEMENT; LONG TERM EXPOSURE; MALE; MORNING DOSAGE; MOUTH; NEUROTOXICITY; NONHUMAN; OROFACIAL DYSKINESIA; RAT; TARDIVE DYSKINESIA; TRUNK;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DOPAMINE; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; MALE; MOTOR ACTIVITY; MOVEMENT DISORDERS; NEOSTRIATUM; RATS; RATS, WISTAR; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47749124933     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.05.003     Document Type: Article

References (57)

1. Acarin L., González B., and Castellano B. Neuronal, astroglial and microglial cytokine expression after an excitotoxic lesion in the immature rat brain. Eur J Neurosci 12 (2000) 3505-3520
2. Andreassen O.A., and Jorgensen H.A. Neurotoxicity associated with neuroleptics induced oral dyskinesia in rats, implications for tardive dyskinesia. Prog Neurobiol 65 (2000) 525-531
3. Andreassen O.A., Ferrante R.J., Beal M.F., and Jørgensen H.A. Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid. Neuroscience 87 3 (1998) 639-648
4. Andreassen O.A., Waage J., Finsen B., and Jørgensen H.A. Memantine attenuates the increase in striatal preproenkephalin mRNA expression and development of haloperidol-induced persistent oral dyskinesias in rats. Brain Res 994 (2003) 188-192
5. Bishnoi M., Chopra K., and Kulkarni S.K. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia-A biochemical and neurochemical study. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 1130-1138
6. Bishnoi M., Kumar A., Chopra K., and Kulkarni S.K. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia. Indian J Exp Biol 45 (2007) 175-179
7. Bishnoi M., Chopra K., and Kulkarni S.K. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Pharmacol Biochem Behav 88 (2008) 511-522
8. Bloomquist J., King E., Wright A., Mytilineou C., Kimura K., Castagnoli K., et al. 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J Pharmacol Exp Ther 270 (1994) 822-830
9. Burger M.B.E., Fachineto R., Alves A., Callegari L., and Rocha J.B.T. Acute reserpine and sub-chronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats. Brain Res 1031 (2005) 202-210
10. Burger M.B.E., Fachineto R., Zeni G., and Rocha J.B.T. Ebselen attenuates haloperidol induced orofacial dyskinesia and oxidative stress in rat brain. Pharmacol Biochem Behav 81 (2005) 608-615
11. Burkhardt C., Kelly J.P., Lim Y.H., Filley C.M., and Parker W.D. Neuroleptic medications inhibit complex II of the electron transport chain. Ann Neurol 33 (1993) 512-517
12. Burt D.R., Creese I., and Snyder S.H. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196 (1977) 326-328
13. Cadet J.L., and Kahler L.A. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 18 (1994) 457-467 1994
14. Cara DB., Dusticier N., Forni C., Lievens J.C., and Daszuta A. Serotonin depletion produces long lasting increase in striatal glutamatergic transmission. J Neurochem 78 (2001) 240-248
15. Casey D.E. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology (Berl) 112 (1993) S55-S59
16. Casey D.E. Tardive Dyskinesia: pathophysiology. In: Foyd E., Bloom, and Kupfer D.J. (Eds). Psychopharmacology: the fourth generation of progress (1995), Raven press, New York 1497-1502
17. Casey D.E. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 61 (2000) 5-9
18. Church W.H. Column chromatography analysis of brain tissue: an advanced laboratory exercise for neuroscience majors. J Undergrad Neurosci Educ 3 (2005) A36-A41
19. Coyle J.T., and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262 (1993) 689-695
20. Drucker G.E., Ritzmann R.F., Wichlinski L.J., Engh K., Gordon J.H., and Fields J.Z. Prevention and reversal of dopamine receptor supersensitivity by cyclo(leucyl-glycyl) (CLG): biphasic dose-response curves. Pharmacol Biochem Behav 47 (1994) 141-145
21. Felszeghy K., Banisadr G., Rostene W., Nyakas C., and Haour F. Dexamethasone downregulate chemokine receptor CXCR4 and exerts neuroprotection against hypoxia/ischemia-induced brain injury in neonatal rats. Neuroimmunomodulation 11 (2004) 404-413
22. Gale K. Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature 283 (1980) 569-570
23. Golde S., Coles A., Lindquist J.A., and Compston A. Decreased iNOS synthesis mediates dexamethasone-induced protection of neurons from inflammatory injury in vitro. Eur J Neurosci 18 (2003) 2527-2537
24. Guerin-Marchand C., Sénéchal H., Pelletier C., Fohrer H., Olivier R., David B., et al. H2O2 impairs inflammatory mediator release from immunologically stimulated RBL-2H3 cells through a redox-sensitive, calcium-dependent mechanism. Inflamm Res 50 (2001) 341-349
25. Ikeda H., Adachi K., Hasegawa M., Sato M., Hirose N., Koshikawa N., et al. Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia. J Neural Transm 106 (1999) 1205-1216
26. Kane J. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: the fourth generation of progress (1995), Raven press, New York 1485-1495
27. Kikumori T., Kambe F., Nagaya T., Funahashi H., and Seo H. Thyrotrophin modifies activation of nuclear factor kappaB by tumor necrosis factor-alpha in rat thyroid cell line. Biochem J 354 (2001) 573-579
28. Klawans H.L., and Rubovits R. An experimental model of tardive dyskinesia. J Neural Trans 33 (1972) 235-246
29. Kulkarni S.K., and Naidu P.S. Tardive dyskinesia: an update. Drugs Today (Barc) 37 (2001) 97-119
30. Kulkarni S.K., Arzi A., and Kaul P.N. Modification of drug-induced catatonia and tremors by quapazine in rats and mice. Jpn J Pharmacol 30 (1980) 129-135
31. Lowry O.H. Protein measurements with the folin-phenol reagent. J Biol Chem 193 (1951) 265-275
32. Meshul C.K., and Tan S.E. Haloperidol-induced morphological alterations are associated with changes in calcium/calmodulin kinase II activity and glutamate immunoreactivity. Synapse 18 3 (1994) 205-217
33. Meshul C.K., Janowsky A., Casey D.E., Stallbaumer R.K., and Taylor B. Coadministration of haloperidol and SCH-23390 prevents the increase in "perforated" synapses due to either drug alone. Neuropsychopharmacology 7 (1992) 285-293
34. Mitchell I.J., Cooper A.C., Griffiths M.R., and Cooper A.J. Acute administration of haloperidol induces apoptosis of neurons in the striatum and substantia nigra in the rat. Neuroscience 109 1 (2002) 89-99
35. Moots R.J., Al-Saffar Z., Hutchinson D., Golding S.P., Young S.P., Bacon P.A., et al. Old drug, new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Ann Rheum Dis 58 (1999) 585-597
36. Naidu P.S., Singh A., and Kulkarni S.K. Quercetin, a bioflavonoid attenuated haloperidol induced orofacial dyskinesia. Neuropharmacology 44 (2003) 1100-1106
37. Ninan I., and Kulkarni S.K. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics. Methods Find Exp Clin Pharmacol 21 9 (1999) 603-608
38. Paterson G.J., Ohashi Y., Reynolds G.P., Pratt J.A., and Morris B.J. Selective increases in the cytokine, TNFalpha, in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs. J Psychopharmacol 20 (2006) 636-642
39. Pillai A., Parikh V., Terry Jr. A.V., and Mahadik S.P. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. Psychiatr Res 41 5 (2007) 372-386
40. Polydoro M., Schröder N., Lima M.N., Caldana F., Laranja D.C., Bromberg E., Roesler R., Quevedo J., Moreira J.C., and Dal-Pizzol F. Haloperidol- and clozapine-induced oxidative stress in the rat brain. Pharmacol Biochem Behav 78 4 (2004) 751-756
41. Post A., Holsboer F., and Behl C. Induction of NF-B activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-B and neuroprotection by antioxidants. J Neurosci 15 (1998) 8236-8246
42. Post A., Rücker M., Ohl F., Uhr M., Holsboer F., Almeida O.F., et al. Mechanisms underlying the protective potential of alpha-tocopherol (vitamin E) against haloperidol-associated neurotoxicity. Neuropsychopharmacology 26 (2002) 397-407
43. Prehn J.H., Welsch M., Backhauss C., Nuglisch J., Ausmeier F., Karkoutly C., and Krieglstein J. Effects of serotonergic drugs on experimental brain ischemia: evidence for the protective role of serotonin in cerebral ischemia. Brain Res 630 (1993) 10-20
44. Rajakumar G., Naas F., Johnson R.L., Chiu S., Yu K.L., and Mishra R.K. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of l-prolyl-l-leucyl-glycinamide (PLG). Peptides 8 (1987) 855-861
45. Reddy D.S., and Kulkarni S.K. Possible role of nitric oxide in the nootropic and antiamnesic effects of neurosteroids on aging and dizocilpine induced learning impairment. Brain Res 799 (1998) 215-219
46. Reinke A., Martins M.R., Lima M.S., Moreira J.C., Dal-Pizzol F., and Quevedo J. Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett 372 1-2 (2004) 157-160
47. Rollema H., Skolnik M., D'Engelbronner J., Igarashi K., Usuki E., and Castagnoli Jr. N. MPP (+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 268 (1994) 380-387
48. Saldaña M., Bonastre M., Aguilar E., and Marin C. Role of nigral NFkappaB p50 and p65 subunit expression in haloperidol-induced neurotoxicity and stereotyped behavior in rats. Eur Neuropsychopharmacol 16 (2006) 491-497
49. Schaaf M.J., Willetts L., Hayes B.P., Maschera B., Stylianou E., and Farrow S.N. The relationship between intranuclear mobility of the NF-B subunit p65 and its DNA-binding affinity. J Biol Chem 281 (2006) 22409-22420
50. See R.E., and Lynch A.M. Chronic haloperidol potentiates stimulated glutamate release in caudate putamen, but not prefrontal cortex. Neuroreport 6 (1995) 1795-1798
51. Semkova I., Wolz P., and Krieglstein J. Neuroprotective effect of 5HT-1A receptor agonist, Bay X 3702, demonstrated invitro and invivo. Euro J Pharmacol 359 (1998) 251-260
52. Skoblenick K.J., Castellano J.M., Rogoza R.M., Dyck B.A., Thomas N., Gabriele J.P., Chong V.Z., and Mishra R.K. Translocation of AIF in the human and rat striatum following protracted haloperidol, but not clozapine treatment. Apoptosis 11 5 (2006) 663-672
53. Tsai G., and Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42 (2002) 165-179
54. Tsai G., Goff D.C., Wang R.W., Flood J., Baer L., and Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 155 (1998) 1207-1213
55. Waddington J.L. Do D2-like dopamine receptors mediate neuronal excitation or inhibition: some functional-behavioural implications?. Nihon Shinkei Seishin Yakurigaku Zasshi 17 (1997) 111-112
56. Yang J.T., Lee T.H., Weng H.H., Chang C.N., Chen W.C., Cheng W.C., et al. Dexamethasone enhances NT-3 expression in rat hippocampus after traumatic brain injury. Exp Neurol 192 (2005) 437-443
57. Yokoyama H., Kasai N., Ueda Y., Niwa R., Konaka R., Mori N., et al. In vivo analysis of hydrogen peroxide and lipid radicals in the striatum of rats under long-term administration of a neuroleptic. Free Radic Biol Med 24 (1998) 1056-1060